Patents by Inventor Dong-Kwon Rhee

Dong-Kwon Rhee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition comprising attenuated strains and use thereof
    Patent number: 11826413
    Abstract: Provided is a pharmaceutical composition including attenuated Streptococcus pneumoniae strains, and a method thereof for prevention or treatment of inflammatory diseases, respiratory viral infections, bacterial infectious diseases, or allergic diseases.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: November 28, 2023
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Dong-Kwon Rhee, Seung-Han Seon, Bo-Gyung Kim
  • PHARMACEUTICAL COMPOSITION COMPRISING ATTENUATED STREPTOCOCCUS PNEUMONIAE STRAINS AND USE THEREOF
    Publication number: 20210379175
    Abstract: Provided is a pharmaceutical composition including attenuated Streptococcus pneumoniae strains, and a method thereof for prevention or treatment of inflammatory diseases, respiratory viral infections, bacterial infectious diseases, or allergic diseases.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 9, 2021
    Inventors: Dong-Kwon RHEE, Seung-Han SEON, Bo-Gyung KIM
  • Pharmaceutical composition comprising attenuated strains and use thereof
    Patent number: 11135278
    Abstract: Provided is a pharmaceutical composition including attenuated Streptococcus pneumoniae strains, and a method thereof for prevention or treatment of inflammatory diseases, respiratory viral infections, bacterial infectious diseases, or allergic diseases.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: October 5, 2021
    Assignee: DOKNIP BIOPHARM CO.
    Inventors: Dong-Kwon Rhee, Seung-Han Seon, Bo-Gyung Kim
  • PHARMACEUTICAL COMPOSITION COMPRISING ATTENUATED STREPTOCOCCUS PNEUMONIAE STRAINS AND USE THEREOF
    Publication number: 20200282039
    Abstract: Provided is a pharmaceutical composition including attenuated Streptococcus pneumoniae strains, and a method thereof for prevention or treatment of inflammatory diseases, respiratory viral infections, bacterial infectious diseases, or allergic diseases.
    Type: Application
    Filed: April 25, 2018
    Publication date: September 10, 2020
    Inventors: Dong-Kwon RHEE, Seung-Han SEON, Bo-Gyung KIM
  • Vaccine comprising recombinant CLPP protein of
    Patent number: 8828409
    Abstract: A method for immunizing a human or animal against pneumococcal infections, comprising by administering a vaccine comprising a purified recombinant caseinolytic protease P (ClpP) protein of S. pneumoniae in an immunologically effective amount to the human or animal.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: September 9, 2014
    Assignees: Sungkyunkwan University, Adelaide Research & Innovation Pty Ltd.
    Inventors: Dong-Kwon Rhee, Hyeok-Young Kwon, Mu-Hyeon Choi, Abiodun David Ogunniyi, James Cleland Paton
  • VACCINE COMPRISING RECOMBINANT CLPP PROTEIN OF STREPTOCOCCUS PNEUMONIAE
    Publication number: 20110129501
    Abstract: A method for immunizing a human or animal against pneumococcal infections, comprising by administering a vaccine comprising a purified recombinant caseinolytic protease P (ClpP) protein of S. pneumoniae in an immunologically effective amount to the human or animal.
    Type: Application
    Filed: November 24, 2010
    Publication date: June 2, 2011
    Inventors: Dong-Kwon Rhee, Hyeok-Young Kwon, Mu-Hyeon Choi, Abiodun David Ogunniyi, James Cleland Paton
  • Vaccine Comprising Recombinant Clpp Protein of Streptococcus Pneumoniae
    Publication number: 20080292662
    Abstract: This invention is about vaccine comprising recombinant CLPP protein of Streptococcus pneumoniae. In this study, it was demonstrated that the CLPP was translocated into the cell wall after heat shock. And the immunization of mice with the pneumococcal CLPP prior to challenge with virulent D39 elicited protective immunity against systemic disease to a level comparable to that obtained with the well-characterized pneumococcal protein vaccine candidates, PSPA and Ply. Thus the pneumococcal CLPP can be used as an antigen for vaccine.
    Type: Application
    Filed: December 31, 2003
    Publication date: November 27, 2008
    Applicants: SUNGKYUNKWAN UNIVERSITY, ADLAIDE RESEARCH & INNOVATION PTY LTD (ARI)
    Inventors: Dong-Kwon Rhee, Hyeok-Young Kwon, Mu-Hyeon Choi, Abiodun David Ogunniyi, James Cleland Paton